The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be ...
This was the stock's third consecutive day of losses.
Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...
This was the stock's second consecutive day of losses.
While Regeneron records net product sales of Eylea in the United States, Bayer does the same outside the United States. The company also records its share of profits/losses in connection with ...
Two biotech companies failed to reverse orders barring them from selling biosimilars of Regeneron’s eye disease drug Eylea in rulings from a federal appeals court … ...
The company has amassed 150 staff to sell Journavx, which it priced at $15.50 per pill, or about $30 per day. Cost and patient access are concerns with most new medicines, but they can be especially ...
Then, on October 31, 2024, Regeneron announced financial results for Q3 2024 that included disappointing U.S. net sales for its EYLEA and EYLEA HD products. The company revealed that those sales ...
SAN FRANCISCO — Just over 20 years ago, the people of California voted to spend billions of dollars on an exciting new idea to remake medicine … ...
Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Regeneron investors who were adversely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback
